Three dierent novel BRCA1 mutations, ®ve independent cases of the same 12 bp insertion-duplication in intron-20 and two novel rare BRCA1 sequence variants were identi®ed among 122 Polish women with positive, in most cases moderate family history of breast and/or ovarian cancer, 80 controls and 34 unselected breast cancer tissue specimens. All mutations and variants were germline. The 4153 delA frameshift mutation, the Tyr105Cys missense mutation and two cases of the alteration in intron-20 were found in the group of healthy women with positive family history. Two other cases of the intronic insertion were found in unselected controls. Their carriers had no family history of breast or ovarian cancer but other cancers occurred in their families. The 1782 Trp/STOP nonsense mutation and one case of the insertion in intron-20 were ®rst found in tissue specimens of breast cancer patient and breast/ovarian cancer patient, respectively. Their carriers also had no family history of breast or ovarian cancer. The distribution of the insertion in intron-20 in analysed groups and results of RT ± PCR experiments suggest a less prominent role for this variant considered earlier a splicing mutation. This study shows also, that more population-oriented research is needed, involving women with less profound or even no family history of breast and ovarian cancer, to better understand the role and signi®cance of dierent BRCA1 variants and mutations.
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Introduction
Approximately one in ten women in western countries will develop breast cancer during their lifetime . In most cases the disease is sporadic; however, some 5 ± 10% of women with breast cancer inherit increased susceptibility to the disease (Claus et al., 1991) . Within this fraction of breast cancer the germline mutations in BRCA1 (Miki et al., 1994) and BRCA2 genes most frequently form a favorable genetic background for the disease. Also at increased risk are the carriers of one abnormal allele of the ataxia telangiectasia gene (Swift et al., 1991) , the carriers of rare minisatelite allele at the HRAS1 locus (Krontiris et al., 1993) and the members of Li Fraumeni families with germline mutation in the p53 gene (Srivastava et al., 1990) .
The BRCA1 gene located on chromosome 17q21 (Hall et al., 1990) is also linked to hereditary ovarian cancer (Narod et al., 1991) . More than 400 BRCA1 sequence variants have been identi®ed thus far and deposited in Breast Cancer Information Core Database (Friend et al., 1995) which now contains about 150 dierent cancer predisposing mutations. Most of this knowledge comes from studies of breast and breastovarian cancer families. Therefore the known mutations are probably biased towards those with more severe eects on phenotype. It is expected that less expressive mutations will be identi®ed when studies expand and include women with less profound family history and women from the general population. It is also very likely that the incidence of BRCA1 mutations in dierent ethnic groups will vary and that dierent mutations will occur in populations from dierent geographical regions. First indications of that come from the studies of Jewish women of Eastern European descent and from the analysis of Swedish (Johannsson et al., 1996) and Austrian breast cancer families.
As most women have no close relative with breast or ovarian cancer, a positive family history of these diseases is one of the primary risk factors. Thus, for women with one aected ®rst-degree relative, the risk of developing the disease is increased by 1.5-3 times (Thompson, 1994) . In this paper we describe the results of BRCA1 gene analysis in a group of Polish women selected for increased risk of breast and ovarian cancer based on their family history. We have also examined a substantial number of unselected controls and a set of breast cancer tissue samples. sites, were ampli®ed from individual genomic DNA samples and screened for sequence variations by combined single strand conformation polymorphism and heteroduplex analysis ± SSCP ± HDX. The observed variants were sequenced, each along with the corresponding normal fragment. The sequencing results for most interesting variants are shown in Figure 1 .
Three novel BRCA1 mutations identi®ed in this study and the characteristics of women in whom these mutations were found are shown in Table 1 . Five independent cases of the same intron-20 alteration are also included in the table. Every type of mutation is represented: frameshift, nonsense, missense and the potential splicing mutation. The latter is very interesting as the 12 bp duplication-insertion in intron-20 is observed in our study at unusually high frequency.
In an attempt to clarify the molecular outcome of this intronic insertion we have performed the following RT ± PCR experiment. The blood cDNA of the carriers and controls was ampli®ed with primers located in BRCA1 exons 19 and 22, to see whether any shorter or longer fragment would appear from carrier's cDNA. That would re¯ect either exon skipping, cryptic site activation or intron retention during splicing of RNA transcript from the mutant allele. However, there was no indication of any additional product besides the normal 244 bp fragment.
The nonsense Trp4Stop mutation in exon 22 found in patient 118 truncates the protein of amino acid 1781. The protein does not contain terminal 82 amino acids including 12 residues of the conserved C-terminal domain. The carrier was diagnosed with breast cancer at the age of 40 and underwent surgery. The mutation was ®rst detected in the tumor, then con®rmed in the proband's blood DNA as well as in four out of ®ve family members tested. The SSCP analysis of proband's tumor DNA shows also LOH at the BRCA1 locus (Figure 2) . Interestingly, in the same tumor sample the p53 gene mutation Pro278A1a was earlier found (Krzyz . osiak et al., unpublished) and con®rmed to be somatic. The frameshift mutation at codon 1345 which triggers the protein synthesis termination at codon 1465 was found in the DNA of a healthy 38-year-old woman, case 98. Her mother and the mother's two sisters had breast cancer diagnosed respectively at the age of 47, 52 and 45. Another mother's sister and a grandmother had ovarian cancer, diagnosed respectively at the ages of 62 and 59. The DNA samples from some aected and unaected members of this family could be obtained, and the results of their analysis for codon 1345 mutation are shown in the family pedigree in Figure 3a .
The missense mutation Tyr105Cys in case 91 was the ®rst alteration found in BRCA1 exon 7 (Friend et al., 1995) . We detected the A to G transition at codon 105 in only one out of 236 DNA samples tested. The carrier, a 36-year-old healthy woman, had a father who died of lung cancer at the age of 70 and a brother who died of the same type of cancer at the age of 48. Her mother died of uterine cancer at the age of 43 and the mother's sister died of breast cancer at the age of 56 ( Figure 3b ). The segregation of this amino acid change with the disease in the carrier's family could not be examined as the appropriate DNA samples were not available for analysis. The tyrosine at position 105 in BRCA1 protein lies outside the two regions conserved in human and mouse sequences (Abel et al., 1995) . In murine Brca1 the position 105 is occupied by Phe, similar to Tyr. However, in canine sequence, like in human, tyrosine 105 is present (Szabo et al., 1996) . The none BrCa ± breast cancer, OvCa ± ovarian cancer, UtCa ± uterine cancer, LuCa ± lung cancer, StCa ± stomach cancer, OsSa ± osteosarcoma, Leu ± leukemia, Mel ± melanoma, BCa ± brain cancer (age of diagnosis/age of death) M ± mother, F ± father, S ± sister, B ± brother, GM ± grandmother, MA ± maternal aunt, MU ± maternal uncle 
Novel common polymorphism and rare sequence variants
In this study we have also identi®ed one common polymorphism, which has not been described earlier. This is the C4T transition in intron-7, located 34 bp upstream of the start of exon 8. Its frequency in the studied group is 0.22. One of the rare BRCA1 sequence variants was found in exon 11. It is a silent base change C4T at the third position of serine codon 378. Another rare variant, the T to C transition was found in intron-2, 37 bp from the end of exon 2. Both were detected only once among the 236 DNA samples tested. In a family of the woman with the alteration in intron-2 there was no history of breast or ovarian cancer.
Discussion
In Poland the country-average mortality rate for breast cancer is approximately half of that reported for the United States. The participants of this study, except for patient 271 who was from Upper Silesia, were from the PoznanÂ region in Western Poland where the incidence of breast cancer is the highest in the country (ZatonÂ ski, 1993) . The studied population is representative of the ethnic group inhabiting the Wielkopolska region where the human migration due to historical events has been rather low. The analysis of the BRCA1 gene in 236 women revealed three novel mutations, one novel common polymorphism, two new rare sequence variants and relatively high frequency of the alteration in intron-20. Our data may be considered one of the ®rst insights into the future results of BRCA1 mutation analysis when the research extends to many other ethnic groups and to women with less profound family history of breast and ovarian cancer. The incidence of BRCA1 mutations and the intron-20 alteration in the analysed groups is shown in Figure  4 . The observed high frequency of the 12 bp insertionduplication in intron-20 and its distribution in the studied groups is intriguing. In earlier reports this insertion was in each case associated with the serious medical history of malignant conditions and was not detected in numerous controls (Takahashi et al., 1995; Langston et al., 1996a; Langston et al., 1996b) . In one of these studies the carrier was a woman with both breast and ovarian cancer who had ®ve maternal relatives with breast cancer (Takahashi et al., 1995) . In the other study this insertion was found in a young 31-year-old women diagnosed with breast and cervical cancer (Langston et al., 1996a) . Most recently two other cases of this insertion were found in men with prostate cancer (Langston et al., 1996b) . Their ages were 46 and 51 at diagnosis. Only one out of ®ve Polish women with this insertion, patient 271, resembles in this respect the earlier described cases. This patient had breast cancer diagnosed at the age of 37 and ovarian cancer at the age of 39. The other four carriers are healthy, however, they have a signi®cant but diverse family history of various cancers. The pedigrees of Polish families with this insertion are shown in Figure 5 .
As shown in this study the 12 bp insertionduplication does not appear to cause aberrant splicing of RNA transcript in blood tissue. Nevertheless it is possible that it impairs splicing in other tissues e.g. Figure 3 Pedigrees of two families, 98 (a) and 91 (b), with BRCA1 frameshift mutation 4153de1A and missense mutation Tyr105Cys, respectively. Circles represent females and squares represent males. Left-and right-side-blackened symbols represent women aected with breast and ovarian cancer, respectively. The upper-side-blackened symbols represent any other cancer. The type of cancer is given below the circle and square symbols: BrCa ± breast cancer, OvCa ± ovarian cancer, BCa ± brain cancer, UtCA ± uterine cancer, LuCa ± lung cancer. The slashed symbols indicate individuals who are deceased. Age at diagnosis and age at death, or current age of the analysed patients are given in bracket under the patient symbol. Black vertical line through a symbol indicates carriers of mutation, while Wt indicates analysed cases who are noncarriers. Arrowhead indicates proband in each family Figure 4 The incidence of BRCA1 mutations in the analysed sample: women with positive family history of breast and/or ovarian cancer (FH); tumor samples (T); controls (C) BRCA1 mutations in Polish women K Sobczak et al ovary or breast. Another possibility is that the insertion aects only the kinetics of splicing and results in a lower level of normal mRNA from the mutant allele. In this context it should be recalled that markedly decreased levels of BRCA1 mRNA were observed in sporadic invasive breast cancers (Thompson et al., 1995) . Alternatively, the 12 bp insertion is only a neutral marker that may or may not be linked to some speci®c high-risk haplotype or to some other cancer predisposing mutation. This problem clearly needs further investigation. The example of the relatives of patient 118 with the de®nite mutation in exon 22 shows that in the family with no reported history of breast or ovarian cancer the BRCA1 mutation carriers were identi®ed through the analysis of tumor tissue of the aected family member (Figure 2) . Thus, the screening of cancer samples ± even those unselected for family history ± may be considered as an eective way of identifying those at high risk who are at increased need for a preventive intervention. The contribution of such carriers to the overall incidence of BRCA1 mutations is as yet unknown. In two recent studies the incidence of mutations was found to be 13% in women with breast cancer diagnosed before the age of 30 (FitzGerald et al., 1996) and 10% in women diagnosed with breast cancer under the age of 35 (Langston et al., 1996a) . Two out of six mutation carriers from the latter study did not report any family history of breast or ovarian cancer. The average age of breast cancer diagnosis in our sample of 34 women was 56, and this group included only four women with cancer diagnosed at the age of 40 or earlier. Patient 118 was one, diagnosed with in®ltrating lobular carcinoma at the stage IIA. As mentioned earlier in this paper, the tumor tissue DNA of this patient harbors also the somatic mutation in the p53 gene. This C to G transversion replaces Pro for Ala at codon 278. The Pro 278 nucleates the H2 helix in p53 core domain crystal structure (Cho et al., 1994) , is present in a conserved region V and is identical in p53 proteins from diverse species (Friend, 1994) . This missense mutation seems therefore to be functionally signi®cant. Our ®nding gives new insight into the molecular mechanism of tumor development in epithelial cells of the breast and shows that during the process of multistep carcinogenesis, the p53 gene mutation can also occur in the background of mutated BRCA1.
From the perspective of genetic testing, the spectrum of BRCA1 mutations identi®ed thus far looks complicated. The distribution of mutations, although uneven in various BRCA1 sequence regions, does not allow focusing the analysis on some exons while omitting the other. Of the methods used for mutation detection, besides direct sequencing, the protein truncation test gives good results, as about 95% of known mutations lead to truncated proteins (Friend et al., 1995) . Also the SSCP technique when combined with heteroduplex analysis is capable of detecting the majority of missense, nonsense and splicing mutations and perhaps all frameshift mutations. Simplicity is one of the advantages of the latter technique which is amenable to multiplexing and to analysing PCR products obtained from pooled genomic DNA samples (Koz owski et al., 1996) . These factors will become important if the search for dispersed mutations in BRCA1 and BRCA2 genes is scaled up, before the DNA chip technology (Hacia et al., 1996) becomes mature and widely available.
Further research on dierent ethnic groups should involve a higher number of women with positive family history of breast and ovarian cancer, divided into several more homogenous risk groups, and more controls representing the general population. A high number of unselected, consecutive breast and ovarian cancer tissue specimens should be subjected to a similar analysis. This will allow an experimental veri®cation of the crude estimates regarding the contribution of hereditary factors to the overall incidence of these cancers. A systematic search for somatic mutations in other tumor suppressor genes and oncogenes in these tissue specimens, will help distinguishing between the cancers with and without the hereditary background.
Materials and methods

Patients and cancer tissue characteristics
The volunteers of this study were among the women who underwent the mammography screening at the Wielkopolska Cancer Center in winter 1995. The initial selection was based on direct interviews, and the number of reported cases of breast or ovarian cancers among ®rst-and seconddegree relatives was con®rmed wherever possible by medical records. The predominant part of the analysed sample were 122 healthy women of an average age of 38, range 18 ± 67, with a varying degree of family history of l Figure 5 Pedigrees of families 58, 69, 75, 82 and 271, carrying the 12 bp insertion-duplication in intron 20. The symbols used are as described in legend to Figure 3 , except for: StCa ± stomach cancer, Le ± leukemia, OsCa ± osteosarcoma, Mel ± melanoma breast and ovarian cancer. This group included women in whose families one case of breast cancer occurred among the ®rst and second degree relatives (70), and women from families in which one case of ovarian cancer occurred (4). There were also 48 women with a more signi®cant family history. Among their relatives occurred two cases of breast cancer (20), two cases of ovarian cancer (2), one case of breast and one of ovarian cancer (13), three breast cancers or two breast and one ovarian (10), four and ®ve cases of breast and ovarian cancer (3). The control group was composed of 80 women unselected for family history of breast or ovarian cancer. The blood samples were collected and the con®dentiality of the patients was preserved in accordance with the guidelines for studies of human subjects (Hoskins et al., 1995) . Women who participated in this study, were informed about its goals, and oered counseling and education about the known risk factors of cancer and potential risks as well as the bene®ts of genetic testing . This study included also 34 breast cancer tissue specimens that were earlier analysed for mutations in the p53 and p16 genes. The tissue specimens were from patients, unselected for the age of diagnosis, who underwent surgery at the Wielkopolska Cancer Center in PoznanÂ . The average age at diagnosis was 56 years (range 29 ± 82). They were diagnosed at stage I (5), IIA (13), IIB (9), IIIA (5) and IIIB (2).
PCR ± SSCP ± HDX analysis and sequencing
Forty-nine PCR primer pairs were used, those for exons 1 ± 10 and 12 ± 24 were adapted from the literature (Friedman et al., 1994) . Exon 11 was covered with 26 newly designed primer pairs giving partially overlapping PCR products of the average size 230 bp ( Table 2 ). The protocol for rapid and economical PCR was used in all ampli®cations (Sobczak et al., 1995) . All variant bands except for those originating from known common polymorphisms were con®rmed in three independent PCR-SSCP-HDX experiments.
PCR ampli®cations were carried out in a volume of 5 ml containing 25 ng of genomic DNA, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris/HCl (pH 8.3), 200 mM of each dNTP and 0.125 U Taq polymerase (Perkin Elmer/Cetus). PCR primers used at concentration 1 mM were 5'-end labeled with [g-32 P]ATP and T4 polynucleotide kinase (New England BioLabs) prior to PCR . Amplifications done on a Perkin Elmer-Cetus 480 Thermal Cycler involved 35 cycles: 1s/948C, 1s/558C and 10s/728C. The annealing temperature was dierent: 508C for exon 8, 578C for exons 1, 3, 4 and 648C for fragment four of exon 11. The SSCP-HDX analysis was carried out as described earlier (Koz owski et al., 1996) . The con®rmed variant bands were cut o from the gel, reampli®ed and sequenced from both ends using amplimers as sequencing primers.
RT ± PCR
Reverse transcription of the total RNA isolated from the blood of the four healthy women with the 12 bp insertion in intron-20 and from two control individuals was done with oligo-dT primer and AMV reverse transcriptase (Promega). The PCR primers used to analyse the eect of this insertion on splicing were F19: 5'-GTGACCCAGTC-TATTAAAGAAAGA-3' and R22: 5'-GGGTGAATGAT-GAAAGCTC-3', ampli®cation conditions: 1s/948C, 1s/ 578C, 10s/728C, 35 cycles. Pharmaceutical Co., Ltd., Tsukuba Techno-Park, Ohkubo 3, Tsukuba 300-33, Japan. 
